Related Experiment Videos
Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1
1Department of Medicine, University of California, Irvine 92717.
Abstract:
Pancreatic cancer is an extremely aggressive malignancy. The factors allowing human pancreatic cancer cells to escape normal growth constraints are not known. However, it has been proposed that certain cancer cells may obtain a growth advantage as the result of a lack of responsiveness to negative growth regulators such as transforming growth factor-beta 1 (TGF-beta 1). We now show that two established pancreatic carcinoma cell lines, COLO 357 and PANC-I, are sensitive to growth inhibition by TGF-beta 1. The growth of COLO 357 cells is inhibited by 50% when incubated in the presence of TGF-beta 1 (5 ng/ml) under low serum conditions (0.5%). PANC-I cells are growth inhibited by 25% under the same conditions. In COLO 357 cells, but not PANC-I cells, TGF-beta 1 also causes a marked alteration in cell morphology. In both cell lines, TGF-beta 1 induces TGF-beta 1 mRNA levels in a time and dose-dependent manner. However, TGF-beta 1 does not increase the amount of TGF-beta 2 or TGF-beta 3 mRNA in these cells. In spite of its growth inhibitory effects, TGF-beta 1 fails to suppress c-myc mRNA levels. These findings suggest that TGF-beta 1 inhibits the growth of human pancreatic cancer cells and point to a significant dysfunction in the ability of TGF-beta 1 to suppress c-myc expression in these cells.
Insights
Transforming growth factor-beta 1 (TGF-beta 1) inhibits pancreatic cancer cell growth. However, it fails to suppress c-myc expression, indicating a key cellular dysfunction in these aggressive malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Pancreatic cancer is highly aggressive, with mechanisms of uncontrolled growth poorly understood.
- Insensitivity to negative growth regulators like TGF-beta 1 is a proposed mechanism for cancer cell proliferation.
- The role of TGF-beta 1 in human pancreatic carcinoma cell growth regulation requires further investigation.
Purpose of the Study:
- To investigate the sensitivity of human pancreatic carcinoma cell lines to TGF-beta 1.
- To determine the effects of TGF-beta 1 on cell growth, morphology, and gene expression in pancreatic cancer cells.
- To elucidate potential dysfunctions in TGF-beta 1 signaling pathways in pancreatic cancer.
Main Methods:
- Treatment of COLO 357 and PANC-I pancreatic carcinoma cell lines with TGF-beta 1.
- Assessment of cell growth inhibition under low serum conditions.
- Analysis of cell morphology changes.
- Quantification of TGF-beta 1, TGF-beta 2, TGF-beta 3, and c-myc mRNA levels via RT-PCR.
Main Results:
- TGF-beta 1 significantly inhibited the growth of both COLO 357 (50%) and PANC-I (25%) cells.
- TGF-beta 1 induced morphological alterations in COLO 357 cells.
- TGF-beta 1 upregulated its own mRNA levels in a time- and dose-dependent manner in both cell lines, but not TGF-beta 2 or TGF-beta 3.
- Crucially, TGF-beta 1 failed to suppress c-myc mRNA levels despite its growth inhibitory effects.
Conclusions:
- TGF-beta 1 demonstrates direct growth inhibitory effects on human pancreatic cancer cell lines.
- Pancreatic cancer cells exhibit a significant defect in TGF-beta 1's ability to downregulate c-myc expression.
- This impaired c-myc suppression points to a critical molecular abnormality contributing to pancreatic cancer progression.